July 27, 2015
ARLINGTON, Va. — Today HDMA President and CEO John M. Gray released a statement in support of the recommendations set forth by the Government Accountability Office (GAO) in their report, “Prescription Drugs: More DEA Information About Registrants’ Controlled Substances Roles Could Improve Their Understanding and Help Ensure Access.”
“GAO’s recommendations reaffirm HDMA’s long-standing position that enhanced communication, coordination and collaboration between the DEA and supply chain stakeholders is one of the keys to successfully mitigating prescription drug abuse and diversion. Further, GAO’s findings underscore the importance of the current federal legislation, the Ensuring Patient Access and Drug Enforcement Act of 2015 (H.R. 471/S. 483), which will help strengthen the relationship between supply chain stakeholders and the DEA, while encouraging productive dialogue between all parties. The House passed its version of the bill in April, and we urge the Senate to do the same.
“HDMA and its pharmaceutical distributor members welcome increased transparency with the DEA and are eager to partner with the Administration, and its Acting Administrator Chuck Rosenberg, to develop and implement strategies that ensure access to vital pain medications for legitimate patients, while keeping these products out of the hands of those who abuse them.”
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.